Previous 10 | Next 10 |
Iovance Biotherapeutics (IOVA +11.1%) is on track to end a three-day losing streak recording its biggest intraday gain since June after bullish remarks from Truist on the company’s melanoma candidate lifileucel. Early this week, Instil Bio (NASDAQ:TIL), Iovance’s (NASDAQ:IOVA) r...
Gainers: Ampio Pharmaceuticals (NYSE:AMPE) +22%, 180 Life Sciences (NASDAQ:ATNF) +17%, Brainstorm Cell Therapeutics (NASDAQ:BCLI) +15%, Instil Bio (NASDAQ:TIL) +16%, G Medical Innovations (NASDAQ:GMVD) +15%. Losers: Nuwellis (NASDAQ:NUWE) -26%...
Main Study Cohort: Phase 2 clinical trial with registrational intent for patients with advanced melanoma Additional Cohorts : ITIL-168 clinical trial expanded during IND review process with two additional cohorts, broadening the study target population DALL...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Investors will get a test next week when the consumer report index report drops on September 15 to give a read on inflat...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
DALLAS, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today announced that company manag...
- Presented compassionate use study in advanced melanoma demonstrating 67% of subjects achieved an objective response with 19% achieving a complete response - Received orphan drug designation from the U.S. FDA for lead asset ITIL-168 - Developed 21-day manufacturing proces...
Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...
News, Short Squeeze, Breakout and More Instantly...
DALLAS, May 10, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (“Instil”) (Nasdaq: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today reported its first quarter 2024 financial results and provided a corporate update. Recent...
2024-04-16 19:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...